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Promoter DNA hypermethylation contributes to the malignant phenotype
 
in cancer including 
myeloproliferative neoplasms and myeloid
 
leukemia. We hypothesized that aberrant DNA 
methylation also
 
occurs in juvenile myelomonocytic leukemia (JMML) and asked
 
whether it 
is associated with clinical, hematologic or prognostic
 
features of the disease. Denaturing 
liquid chromatography was
 
used to analyze peripheral blood or bone marrow samples from
 
87 
children with JMML and 17 healthy control subjects for changes
 
in DNA methylation at 14 
candidate gene loci (BMP4, CALCA, CDKN1C,
 
CDKN2B, DAPK1, MGMT, MLH1, PAWR, 
RARB, RASA1, RASSF1, RECK,
 
SOCS1, TP73). We identified 4 genes with promoter DNA 
hypermethylation
 
in JMML: BMP4 (34% of cases), CALCA (30%), CDKN2B (28%) and
 
RARB (23%); the other 10 loci were unmethylated. The pattern
 
of hypermethylation of the 4 
genes allowed the categorization
 
of JMML cases into three groups: no methylation (40/87 
patients),
 
intermediate methylation (1 or 2 genes; 29/87 patients) or high
 
methylation (3 or 4 
genes; 18/87 patients). Lineage-specific
 
cell sorting demonstrated that aberrant methylation 
was restricted
 
to clonal cell populations and could be traced back to the CD34+
 
JMML 
progenitor cell compartment. This observation supports
 
the concept that DNA methylation is 
associated with early pathogenetic
 
events in JMML.
 
 
A correlative analysis of methylation groups with clinical or
 
hematologic features showed that 
high methylation was strongly
 
associated with higher age and increased hemoglobin F level
 
at 
diagnosis (both p<0.01). By contrast, there was no significant
 
association with leukocyte 
count, absolute monocytes, platelet
 
count, blast percentage in blood or bone marrow, spleen 
size,
 
karyotype or mutational category (PTPN11, RAS, CBL, NF1). Importantly,
 
the presence 
of hypermethylation at diagnosis predicted cases
 
with poor outcome; the 5-year overall 
survival (OS) in the no
 
/ intermediate / high methylation groups was 0.63 [0.47–0.79] / 0.52 
[0.30–0.74] / 0.24 [0.04–0.44] (p<0.01). Among patients receiving hematopoietic stem cell 
transplantation,
 
hypermethylation characterized cases with significantly increased
 
probability 
of relapse: the 5-year relapse incidence in the
 
no / intermediate / high methylation groups was 
0.22 [0.11–0.45] / 0.21 [0.09–0.50] / 0.69 [0.49–0.96] (p<0.01). The predictive power of high 
methylation was also reflected
 
in a multivariate Cox model for OS that included age at 
diagnosis,
 
sex, platelet count and mutational category as other variables;
 
here methylation was 
the only significant prognostic factor.
 
Furthermore, longitudinal analyses indicated that some 
cases
 
had acquired a higher methylation phenotype at relapse. In summary,
 
we report aberrant 
DNA methylation as the most important molecular
 
predictor of outcome in JMML. We 
suggest that a high-methylation
 
phenotype characterizes an aggressive biologic variant of this
 
leukemia.
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